Geffken Daniel E. 4
4 · Eloxx Pharmaceuticals, Inc. · Filed Apr 22, 2021
Insider Transaction Report
Form 4
Geffken Daniel E.
CHIEF FINANCIAL OFFICER
Transactions
- Award
Non-Qualified Stock Option (right to buy)
2021-04-20+100,000→ 100,000 totalExercise: $2.38Exp: 2026-04-20→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: ratably on a monthly basis on the last calendar day of each month during the first twelve (12) months following the grant date; provided, however, that if the Issuer terminates the Consulting Agreement for the reporting person's services or if the reporting person is no longer servicing the Issuer at any time following the grant date, no further options shall vest following such termination. If the Consulting Agreement or if the services of the reporting person are terminated for cause by the Issuer, then the options shall be forfeited in their entirety.
- [F2]The reporting person will assign the economic interest of this grant to Danforth Advisors, LLC, where he serves as Managing Director.